Survival from breast cancer in England and Wales up to 2001

[1]  R. Roylance,et al.  New drugs for breast cancer. , 2010, British medical bulletin.

[2]  B Rachet,et al.  Survival from cancer of the breast in women in England and Wales up to 2001 , 2008, British Journal of Cancer.

[3]  A. Gennari.  The Impact of New Chemotherapeutic and Hormone Agents on Survival in a Population-based Cohort of Women with Metastatic Breast Cancer , 2008 .

[4]  E. Winer,et al.  Advances in adjuvant endocrine therapy for postmenopausal women. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  K. Gelmon,et al.  The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancer , 2007, Cancer.

[6]  Phuong Dinh,et al.  Trastuzumab for early breast cancer: current status and future directions. , 2007, Clinical advances in hematology & oncology : H&O.

[7]  Monica Morrow,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials , 2007 .

[8]  Bircan Erbas,et al.  The natural history of ductal carcinoma in situ of the breast: a review , 2006, Breast Cancer Research and Treatment.

[9]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[10]  Robert B Livingston,et al.  Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. , 2005, Journal of the National Cancer Institute.

[11]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[12]  T. McCready,et al.  Breast self-examination and breast awareness: a literature review. , 2005, Journal of clinical nursing.

[13]  C. Gillis,et al.  Why does specialist treatment of breast cancer improve survival? The role of surgical management , 2004, British Journal of Cancer.

[14]  P. Gøtzsche.  On the benefits and harms of screening for breast cancer. , 2004, International journal of epidemiology.

[15]  M. Baum.  Commentary: false premises, false promises and false positives--the case against mammographic screening for breast cancer. , 2004, International journal of epidemiology.

[16]  K. Cheng,et al.  Social deprivation and breast cancer. , 2003, Journal of public health medicine.

[17]  P. Gøtzsche,et al.  Regular self-examination or clinical examination for early detection of breast cancer. , 2003, The Cochrane database of systematic reviews.

[18]  Peter C Gøtzsche,et al.  Cochrane review on screening for breast cancer with mammography , 2001, The Lancet.

[19]  K. Kerlikowske,et al.  Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. , 2000, Archives of internal medicine.

[20]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[21]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[22]  H. Welch,et al.  Using Autopsy Series To Estimate the Disease Reservoir for Ductal Carcinoma in Situ of the Breast: How Much More Breast Cancer Can We Find? , 1997, Annals of Internal Medicine.

[23]  R. Blanks,et al.  Results from the NHS Breast Screening Programme 1990–1993 , 1995, Journal of medical screening.

[24]  R. Peto,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. , 1989, The New England journal of medicine.

[25]  Jack Cuzick,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .

[26]  CONTROLLED TRIAL OF TAMOXIFEN AS SINGLE ADJUVANT AGENT IN MANAGEMENT OF EARLY BREAST CANCER Analysis at Six Years by Nolvadex Adjuvant Trial Organisation , 1985, The Lancet.

[27]  J. Kelsey,et al.  Exogenous estrogens and other factors in the epidemiology of breast cancer. , 1981, Journal of the National Cancer Institute.